Page 69 - ITPS-7-3

INNOSC Theranostics and
Pharmacological Sciences Designing miRNA ONTs for cardiometabolic pandemics

doi: 10.1161/CIRCRESAHA.121.320296 doi: 10.2174/156802611795165098
90. Malik S, Kumar V, Liu CH, et al. Head on comparison of 101. McVicker RU, O’Boyle NM. Chirality of new drug approvals
Self- and Nano-assemblies of Gamma peptide nucleic acid (2013-2022): Trends and perspectives. J Med Chem.
amphiphiles. Adv Funct Mater. 2022;32(7):2109552. 2024;67(4):2305-2320.
doi: 10.1002/adfm.202109552 doi: 10.1021/acs.jmedchem.3c02239
91. Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, 102. Iwamoto N, Butler DCD, Svrzikapa N, et al. Control of
biodistribution and cell uptake of antisense oligonucleotides. phosphorothioate stereochemistry substantially increases
Adv Drug Deliv Rev. 2015;87:46-51. the efficacy of antisense oligonucleotides. Nat Biotechnol.
2017;35(9):845-851.
doi: 10.1016/j.addr.2015.01.008
doi: 10.1038/nbt.3948
92. Andersson S, Antonsson M, Elebring M, Jansson-Lofmark R,
Weidolf L. Drug metabolism and pharmacokinetic strategies 103. Jahns H, Taneja N, Willoughby JLS, et al. Chirality matters:
for oligonucleotide- and mRNA-based drug development. Stereo-defined phosphorothioate linkages at the termini
Drug Discov Today. 2018;23(10):1733-1745. of small interfering RNAs improve pharmacology in vivo.
Nucleic Acids Res. 2022;50(3):1221-1240.
doi: 10.1016/j.drudis.2018.05.030
doi: 10.1093/nar/gkab544
93. Vervaeke P, Borgos SE, Sanders NN, Combes F. Regulatory
guidelines and preclinical tools to study the biodistribution 104. Liu W, Iwamoto N, Marappan S, et al. Impact of stereopure
of RNA therapeutics. Adv Drug Deliv Rev. 2022;184:114236. chimeric backbone chemistries on the potency and
durability of gene silencing by RNA interference. Nucleic
doi: 10.1016/j.addr.2022.114236
Acids Res. 2023;51(9):4126-4147.
94. McDougall R, Ramsden D, Agarwal S, et al. The nonclinical
disposition and pharmacokinetic/pharmacodynamic doi: 10.1093/nar/gkad268
properties of N-Acetylgalactosamine-conjugated small 105. Ryan CA, Rozners E. Impact of chirality and position of
interfering RNA are highly predictable and build lysine conjugation in triplex-forming peptide nucleic acids.
confidence in translation to human. Drug Metab Dispos. ACS Omega. 2020;5(44):28722-28729.
2022;50(6):781-797.
doi: 10.1021/acsomega.0c04021
doi: 10.1124/dmd.121.000428
106. Del Bene A, D’Aniello A, Tomassi S, et al. Ultrasound-
95. Fairweather S, Rogers M, Stoulig P, et al. Nuclease resistance assisted Peptide Nucleic Acids Synthesis (US-PNAS).
and protein recognition properties of DNA and hybrid PNA- Ultrason Sonochem. 2023;95:106360.
DNA four-way junctions. Biophys Chem. 2022;289:106863.
doi: 10.1016/j.ultsonch.2023.106360
doi: 10.1016/j.bpc.2022.106863
107. Shen W, De Hoyos CL, Sun H, Vickers TA, Liang XH,
96. Demidov VV, Potaman VN, Frank-Kamenetskii MD, Crooke ST. Acute hepatotoxicity of 2’ fluoro-modified
et al. Stability of peptide nucleic acids in human serum and 5-10-5 gapmer phosphorothioate oligonucleotides in mice
cellular extracts. Biochem Pharmacol. 1994;48(6):1310-1313. correlates with intracellular protein binding and the loss of
DBHS proteins. Nucleic Acids Res. 2018;46(5):2204-2217.
doi: 10.1016/0006-2952(94)90171-6
doi: 10.1093/nar/gky060
97. Østergaard ME, De Hoyos CL, Wan WB, et al. Understanding
the effect of controlling phosphorothioate chirality in the 108. Shen W, De Hoyos CL, Migawa MT, et al. Chemical
DNA gap on the potency and safety of gapmer antisense modification of PS-ASO therapeutics reduces cellular
oligonucleotides. Nucleic Acids Res. 2020;48(4):1691-1700. protein-binding and improves the therapeutic index. Nat
Biotechnol. 2019;37(6):640-650.
doi: 10.1093/nar/gkaa031
doi: 10.1038/s41587-019-0106-2
98. Hall J. Future directions for medicinal chemistry in the field
of oligonucleotide therapeutics. RNA. 2023;29(4):423-433. 109. Corey DR, Damha MJ, Manoharan M. Challenges and
opportunities for nucleic acid therapeutics. Nucleic Acid
doi: 10.1261/rna.079511.122
Ther. 2022;32(1):8-13.
99. Funder ED, Albaek N, Moisan A, Sewing S, Koch T.
Refining LNA safety profile by controlling phosphorothioate doi: 10.1089/nat.2021.0085
stereochemistry. PLoS One. 2020;15(6):e0232603. 110. Mangla P, Vicentini Q, Biscans A. therapeutic
oligonucleotides: An outlook on chemical strategies to
doi: 10.1371/journal.pone.0232603
improve endosomal trafficking. Cells. 2023;12(18):2253.
100. Brooks WH, Guida WC, Daniel KG. The significance of
chirality in drug design and development. Curr Top Med doi: 10.3390/cells12182253
Chem. 2011;11(7):760-770. 111. Wan WB, Seth PP. The medicinal chemistry of therapeutic

Volume 7 Issue 3 (2024) 16 doi: 10.36922/itps.3025